A new clinical study indicates that molecular test can pinpoint which patients will have a very low risk of death from breast cancer and that these "ultralow" risk patients could be treated less aggressively, leading to fewer toxic effects.

"This is an important step forward for personalizing care for women with breast cancer," noted the lead author Laura J. Esserman, a breast cancer specialist and surgeon with University of California Health System.